Marinos C Dalakas

List of Publications by Year
in descending order

219 papers	22,136 citations	7568 77 h-index	9345 143 g-index
224 all docs	224 docs citations	224 times ranked	12443 citing authors

#	Article	IF	Citations
1	Polymyositis and dermatomyositis. Lancet, The, 2003, 362, 971-982.	13.7	1,306
2	A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis. New England Journal of Medicine, 1993, 329, 1993-2000.	27.0	1,024
3	A New Approach to the Classification of Idiopathic Inflammatory Myopathy. Medicine (United States), 1991, 70, 360-374.	1.0	889
4	Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy. New England Journal of Medicine, 1990, 322, 1098-1105.	27.0	849
5	Polymyositis, Dermatomyositis, and Inclusion-Body Myositis. New England Journal of Medicine, 1991, 325, 1487-1498.	27.0	844
6	Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurology, The, 2008, 7, 136-144.	10.2	582
7	Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Annals of Neurology, 2001, 50, 195-201.	5.3	577
8	Inflammatory Muscle Diseases. New England Journal of Medicine, 2015, 372, 1734-1747.	27.0	559
9	High-Dose Intravenous Immune Globulin for Stiff-Person Syndrome. New England Journal of Medicine, 2001, 345, 1870-1876.	27.0	396
10	A Long-Term Follow-up Study of Patients with Post-Poliomyelitis Neuromuscular Symptoms. New England Journal of Medicine, 1986, 314, 959-963.	27.0	350
11	Controlled Trial of Plasma Exchange and Leukapheresis in Polymyositis and Dermatomyositis. New England Journal of Medicine, 1992, 326, 1380-1384.	27.0	320
12	Chronic relapsing (Dysimmune) polyneuropathy: Pathogenesis and treatment. Annals of Neurology, 1981, 9, 134-145.	5.3	280
13	Placeboâ€controlled trial of rituximab in IgM antiâ€“myelinâ€associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology, 2009, 65, 286-293.	5.3	274
14	Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases. JAMA - Journal of the American Medical Association, 2004, 291, 2367.	7.4	263
15	A Study of the Interferon Antiviral Mechanism: Apoptosis Activation by the 2â€“5A System. Journal of Experimental Medicine, 1997, 186, 967-972.	8.5	256
16	Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. Journal of Clinical Investigation, 2009, 119, 1806-1813.	8.2	237
17	Neuromuscular diseases associated with human immunodeficiency virus infection. Annals of Neurology, 1988, 23, S38-S48.	5.3	236
18	Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. Journal of Clinical Investigation, 2015, 125, 4160-4170.	8.2	229

#	Article	IF	Citations
19	Intravenous immunoglobulin in neurologyâ€"mode of action and clinical efficacy. Nature Reviews Neurology, 2015, 11, 80-89.	10.1	228
20	Advances in the diagnosis, pathogenesis and treatment of CIDP. Nature Reviews Neurology, 2011, 7, 507-517.	10.1	218
21	Peripheral neuropathy and antiretroviral drugs. Journal of the Peripheral Nervous System, 2001, 6, 14-20.	3.1	208
22	Intravenous Immune Globulin Therapy for Neurologic Diseases. Annals of Internal Medicine, 1997, 126, 721.	3.9	204
23	Guillain-BarrÃ© syndrome: The first documented COVID-19â€"triggered autoimmune neurologic disease. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	201
24	A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Annals of Neurology, 1996, 40, 792-795.	5.3	200
25	Immunopathogenesis of inflammatory myopathies. Annals of Neurology, 1995, 37, 74-86.	5.3	195
26	Polymyositis Associated With AIDS Retrovirus. JAMA - Journal of the American Medical Association, 1986, 256, 2381.	7.4	193
27	Sporadic inclusion body myositisâ€"diagnosis, pathogenesis and therapeutic strategies. Nature Clinical Practice Neurology, 2006, 2, 437-447.	2.5	192
28	The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. , 2004, 102, 177-193.		189
29	Interrelation of inflammation and APP in sIBM: IL-1Î² induces accumulation of Î²-amyloid in skeletal muscle. Brain, 2008, 131, 1228-1240.	7.6	184
30	Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups. Annals of Neurology, 1985, 18, 655-659.	5.3	183
31	Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines. Muscle and Nerve, 1999, 22, 1479-1497.	2.2	183
32	Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain, 2009, 132, 1536-1544.	7.6	182
33	The Stiff-Person Syndrome: An Autoimmune Disorder Affecting Neurotransmission of Î³-Aminobutyric Acid. Annals of Internal Medicine, 1999, 131, 522.	3.9	176
34	Acute axonal Guillain-BarrÃ© syndrome with IgG antibodies against motor axons following parenteral gangliosides. Annals of Neurology, 1995, 38, 218-224.	5.3	166
35	Stiff person syndrome: Advances in pathogenesis and therapeutic interventions. Current Treatment Options in Neurology, 2009, 11, 102-110.	1.8	164
36	Complement in neurological disorders and emerging complement-targeted therapeutics. Nature Reviews Neurology, 2020, 16, 601-617.	10.1	163

#	Article	IF	Citations
37	B cells as therapeutic targets in autoimmune neurological disorders. Nature Clinical Practice Neurology, 2008, 4, 557-567.	2.5	162
38	Antibodies to acidic glycolipids in Guillain-BarrÃ© syndrome and chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences, 1992, 107, 111-121.	0.6	161
39	Immunotherapy of myositis: issues, concerns and future prospects. Nature Reviews Rheumatology, 2010, 6, 129-137.	8.0	151
40	Inflammatory Muscle Diseases. New England Journal of Medicine, 2015, 373, 393-394.	27.0	145
41	Immunocytochemical and virological characteristics of hiv-associated inflammatory myopathies: Similarities with seronegative polymyositis. Annals of Neurology, 1991, 29, 474-481.	5.3	144
42	Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain, 2005, 128, 1887-1896.	7.6	144
43	Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology, 2002, 59, S13-21.	1.1	139
44	Chronic idiopathic ataxic neuropathy. Annals of Neurology, 1986, 19, 545-554.	5.3	136
45	Neurological complications of immune checkpoint inhibitors: what happens when you â€˜take the brakes offâ€™ the immune system. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641879986.	3.5	136
46	Demyelination induced by intraneural injection of human antimyelin-associated glycoprotein antibodies. Muscle and Nerve, 1988, 11, 1169-1176.	2.2	134
47	Inclusion body myositis in HIV-1 and HTLV-1 infected patients. Brain, 1996, 119, 1887-1893.	7.6	134
48	Analysis of GAD65 Autoantibodies in Stiff-Person Syndrome Patients. Journal of Immunology, 2005, 175, 7755-7762.	0.8	133
49	Î²-Amyloid is a substrate of autophagy in sporadic inclusion body myositis. Annals of Neurology, 2007, 61, 476-483.	5.3	126
50	Immunotherapy in myasthenia gravis in the era of biologics. Nature Reviews Neurology, 2019, 15, 113-124.	10.1	123
51	Drug Insight: the use of intravenous immunoglobulin in neurologyâ€”therapeutic considerations and practical issues. Nature Clinical Practice Neurology, 2007, 3, 36-44.	2.5	121
52	Motor cortex excitability in stiff-person syndrome. Brain, 2000, 123, 2231-2239.	7.6	117
53	Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain, 2006, 129, 3270-3276.	7.6	116
54	Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder. BMC Neurology, 2019, 19, 1.	1.8	112

#	Article	IF	Citations
55	Expression of the Costimulatory Molecule BB-1, the Ligands CTLA-4 and CD28, and their mRNA in Inflammatory Myopathies. American Journal of Pathology, 1999, 155, 453-460.	3.8	111
56	Downregulation of TGF-Î²1 mRNA and Protein in the Muscles of Patients with Inflammatory Myopathies after Treatment with High-Dose Intravenous Immunoglobulin. Clinical Immunology, 2000, 94, 99-104.	3.2	111
57	Pathogenetic Mechanisms of Post-Polio Syndrome: Morphological, Electrophysiological, Virological, and Immunological Correlations. Annals of the New York Academy of Sciences, 1995, 753, 167-185.	3.8	110
58	Antiâ€“Glutamic Acid Decarboxylase Antibodies in the Serum and Cerebrospinal Fluid of Patients With Stiff-Person Syndrome. Archives of Neurology, 2004, 61, 902.	4.5	110
59	Antiâ€“SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	110
60	Molecular Immunology and Genetics of Inflammatory Muscle Diseases. Archives of Neurology, 1998, 55, 1509.	4.5	107
61	Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	103
62	Mechanisms of Disease: signaling pathways and immunobiology of inflammatory myopathies. Nature Clinical Practice Rheumatology, 2006, 2, 219-227.	3.2	101
63	Timing and Course of Clinical Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Archives of Neurology, 2010, 67, 802.	4.5	99
64	Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e131.	6.0	98
65	Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Current Opinion in Pharmacology, 2010, 10, 346-352.	3.5	97
66	Dysphagia in Patients with the Post-Polio Syndrome. New England Journal of Medicine, 1991, 324, 1162-1167.	27.0	96
67	Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology, 2006, 67, 1068-1070.	1.1	95
68	Invited Article: Inhibition of B cell functions. Neurology, 2008, 70, 2252-2260.	1.1	95
69	Sensory neuropathy associated with monoclonal immunoglobulin M to GD1b ganglioside. Annals of Neurology, 1992, 31, 683-685.	5.3	93
70	Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology, 2006, 66, S33-S38.	1.1	93
71	Pathogenesis of immune-mediated neuropathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 658-666.	3.8	92
72	Tremor as a Feature of Chronic Relapsing and Dysgammaglobulinemic Polyneuropathies. Archives of Neurology, 1984, 41, 711.	4.5	91

#	Article	IF	Citations
73	Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. Nature Reviews Neurology, 2015, 11, 143-156.	10.1	91
74	Pathogenesis and therapies of immune-mediated myopathies. Autoimmunity Reviews, 2012, 11, 203-206.	5.8	90
75	MHC Class I-Mediated Cytotoxicity Does Not Induce Apoptosis in Muscle Fibers nor in Inflammatory T Cells. Journal of Neuropathology and Experimental Neurology, 1996, 55, 1205-1209.	1.7	86
76	Strokes, thromboembolic events, and IVIg. Neurology, 2003, 60, 1736-1737.	1.1	86
77	Cranial neuropathies and COVID-19. Neurology, 2020, 95, 195-196.	1.1	86
78	Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain, 2004, 127, 1182-1190.	7.6	84
79	Incidence and Prevalence of Major Central Nervous System Involvement in Systemic Lupus Erythematosus: A 3-Year Prospective Study of 370 Patients. PLoS ONE, 2013, 8, e55843.	2.5	83
80	Inclusion body myositis with human immunodeficiency virus infection: Four cases with clonal expansion of viral-specific T cells. Annals of Neurology, 2007, 61, 466-475.	5.3	79
81	A doubleâ€blind, placeboâ€controlled study of rituximab in patients with stiff person syndrome. Annals of Neurology, 2017, 82, 271-277.	5.3	78
82	Reduction of Intraepidermal Nerve Fiber Density (IENFD) in the skin biopsies of patients with fibromyalgia: A controlled study. Journal of the Neurological Sciences, 2014, 347, 143-147.	0.6	76
83	Polymyositis inpatients infected with human T-cell leukemia virus type I: The role of the virus in the cause of the disease. Annals of Neurology, 1994, 36, 643-649.	5.3	75
84	Brain Î³-Aminobutyric Acid Changes in Stiff-Person Syndrome. Archives of Neurology, 2005, 62, 970-4.	4.5	75
85	Practical considerations on the use of rituximab in autoimmune neurological disorders. Therapeutic Advances in Neurological Disorders, 2010, 3, 93-105.	3.5	74
86	Autoimmune ataxic neuropathies (sensory ganglionopathies): Are glycolipids the responsible autoantigens?. Annals of Neurology, 1996, 39, 419-422.	5.3	73
87	Stiff-person syndrome. Current Treatment Options in Neurology, 2003, 5, 79-90.	1.8	73
88	Peripheral neuropathies in Sjogren syndrome: a new reappraisal. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 798-802.	1.9	73
89	Immune mechanisms in chronic inflammatory demyelinating neuropathy. Neurology, 2002, 59, S7-12.	1.1	73
90	The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. Journal of Neurology, 2005, 252, i19-i25.	3.6	72

#	Article	IF	Citations
91	Expression of IFN-Î³-inducible chemokines in inclusion body myositis. Journal of Neuroimmunology, 2003, 141, 125-131.	2.3	69
92	Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628561774664.	3.5	69
93	Pathophysiology of inflammatory and autoimmune myopathies. Presse Medicale, 2011, 40, e237-e247.	1.9	68
94	Basic aspects of neuroimmunology as they relate to immunotherapeutic targets: Present and future prospects. Annals of Neurology, 1995, 37, 2-13.	5.3	67
95	Effect of high-dose intravenous immunoglobulin on serum chemistry, hematology, and lymphocyte subpopulations: Assessments based on controlled treatment trials in patients with neurological diseases. Muscle and Nerve, 1997, 20, 1102-1107.	2.2	66
96	Efficacy of Intravenous Immunoglobulin in Neurological Diseases. Neurotherapeutics, 2016, 13, 34-46.	4.4	66
97	Pathogenesis and Treatment of Anti-MAG Neuropathy. Current Treatment Options in Neurology, 2010, 12, 71-83.	1.8	62
98	A critical update on the immunopathogenesis of Stiff Person Syndrome. European Journal of Clinical Investigation, 2010, 40, 1018-1025.	3.4	60
99	Therapeutic targets in patients with inflammatory myopathies: Present approaches and a look to the future. Neuromuscular Disorders, 2006, 16, 223-236.	0.6	59
100	Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1Î²-induced accumulation of Î²-amyloid and cell death. Brain, 2012, 135, 1102-1114.	7.6	58
101	Immunology of stiff person syndrome and other GAD-associated neurological disorders. Expert Review of Clinical Immunology, 2013, 9, 1043-1053.	3.0	57
102	Electrophysiologic correlations with clinical outcomes in CIDP. Muscle and Nerve, 2010, 42, 492-497.	2.2	56
103	Treatment of ?permanent? muscle weakness in familial hypokalemic periodic paralysis. Muscle and Nerve, 1983, 6, 182-186.	2.2	55
104	Inclusion body myositis and paraproteinemia: Incidence and immunopathologic correlations. Annals of Neurology, 1997, 41, 100-104.	5.3	55
105	Interplay between inflammation and degeneration: Using inclusion body myositis to study â€œneuroinflammationâ€. Annals of Neurology, 2008, 64, 1-3.	5.3	55
106	Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. Journal of Clinical Investigation, 2012, 122, 1393-1402.	8.2	55
107	A Double-Blind, Placebo-Controlled, Trial of Amantadine for the Treatment, of Fatigue in Patients with the, Post-Polio Syndrome. Annals of the New York Academy of Sciences, 1995, 753, 296-302.	3.8	53
108	A neuropsychological assessment of phobias in patients with stiff person syndrome. Neurology, 2005, 64, 1961-1963.	1.1	53

#	Article	IF	Citations
109	IVIg in other autoimmune neurological disorders: current status and future prospects. Journal of Neurology, 2008, 255, 12-16.	3.6	52
110	Rimmed vacuoles with Î²-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): similarities with inclusion body myositis. Human Pathology, 1998, 29, 1128-1133.	2.0	51
111	The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): A small pilot study. Journal of the Neurological Sciences, 2013, 334, 123-125.	0.6	51
112	Current treatment of the inflammatory myopathies. Current Opinion in Rheumatology, 1994, 6, 595-602.	4.3	50
113	Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurology, The, 2003, 2, 22-32.	10.2	50
114	The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199738.	3.5	50
115	Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disorders. Neurology, 2013, 81, 1962-1964.	1.1	49
116	Search for HIV proviral DNA and amplified sequences in the muscle biopsies of patients with HIV polymyositis. Muscle and Nerve, 1993, 16, 408-413.	2.2	48
117	Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial. Lancet Neurology, The, 2018, 17, 689-698.	10.2	48
118	Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. Current Opinion in Neurology, 1999, 12, 403-409.	3.6	48
119	Therapeutic Approaches in Patients with Inflammatory Myopathies. Seminars in Neurology, 2003, 23, 199-206.	1.4	47
120	Advances in the pathogenesis and treatment of patients with stiff person syndrome. Current Neurology and Neuroscience Reports, 2008, 8, 48-55.	4.2	46
121	Immunotherapy of Inflammatory Myopathies: Practical Approach and Future Prospects. Current Treatment Options in Neurology, 2011, 13, 311-323.	1.8	46
122	Terminal latency index in neuropathy with antibodies against myelinâ€associated glycoproteins. Muscle and Nerve, 2007, 35, 196-202.	2.2	45
123	High definition profiling of autoantibodies to glutamic acid decarboxylases GAD65/GAD67 in stiff-person syndrome. Biochemical and Biophysical Research Communications, 2008, 366, 1-7.	2.1	45
124	IgG4-Mediated Neurologic Autoimmunities. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	45
125	Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-BarrÃ© syndrome, myasthenia gravis and dermatomyositis. Journal of Neuroimmunology, 1996, 71, 227-229.	2.3	44
126	The immunobiology of autoimmune encephalitides. Journal of Autoimmunity, 2019, 104, 102339.	6.5	44

#	Article	IF	Citations
127	Gene expression profiling in chronic inflammatory demyelinating polyneuropathy. Journal of Neuroimmunology, 2005, 159, 203-214.	2.3	43
128	A Double-Blind, Placebo-Controlled Trial of High-Dose Prednisone for the Treatment of Post-Poliomyelitis Syndrome. Annals of the New York Academy of Sciences, 1995, 753, 303-313.	3.8	42
129	Electrophysiology in chronic inflammatory demyelinating polyneuropathy with IGIV. Muscle and Nerve, 2009, 39, 448-455.	2.2	42
130	GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders. Journal of Neuroimmunology, 2015, 281, 73-77.	2.3	42
131	B cells in the pathophysiology of autoimmune neurological disorders: A credible therapeutic target. , 2006, 112, 57-70.		40
132	Inflammatory myopathies. Current Opinion in Neurology, 2011, 24, 457-462.	3.6	40
133	Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies. Current Opinion in Neurology, 2020, 33, 545-552.	3.6	40
134	Novel future therapeutic options in Myasthenia Gravis. Autoimmunity Reviews, 2013, 12, 936-941.	5.8	39
135	GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110034.	3.5	39
136	Mechanistic Effects of IVIg in Neuroinflammatory Diseases: Conclusions Based on Clinicopathologic Correlations. Journal of Clinical Immunology, 2014, 34, 120-126.	3.8	38
137	Common variable immunodeficiency and inclusion body myositis: A distinct myopathy mediated by natural killer cells. Annals of Neurology, 1995, 37, 806-810.	5.3	37
138	Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications. Frontiers in Immunology, 2021, 12, 627285.	4.8	37
139	Paraneoplastic anti-NMDAR encephalitis: long term follow-up reveals persistent serum antibodies. Journal of Neurology, 2011, 258, 1568-1570.	3.6	36
140	Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy. Neurotherapeutics, 2021, 18, 2397-2418.	4.4	36
141	Postherpes simplex encephalitis: a case series of viral-triggered autoimmunity, synaptic autoantibodies and response to therapy. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641876877.	3.5	33
142	Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies. Neurotherapeutics, 2022, 19, 832-847.	4.4	33
143	Future perspectives in target-specific immunotherapies of myasthenia gravis. Therapeutic Advances in Neurological Disorders, 2015, 8, 316-327.	3.5	32
144	HMGB1 and RAGE in skeletal muscle inflammation: Implications for protein accumulation in inclusion body myositis. Experimental Neurology, 2015, 271, 189-197.	4.1	32

#	Article	IF	Citations
145	Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease. Journal of Neuroimmunology, 2015, 289, 8-11.	2.3	30
146	Progress and stiff challenges in understanding the role of GAD-antibodies in stiff-person syndrome. Experimental Neurology, 2013, 247, 303-307.	4.1	28
147	Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives. Expert Review of Clinical Immunology, 2013, 9, 1125-1133.	3.0	27
148	Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies. Journal of the Peripheral Nervous System, 2012, 17, 34-39.	3.1	26
149	Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: Quantitative assessment of inflammation and Î²â€amyloid in the muscle. Arthritis and Rheumatism, 2012, 64, 4094-4103.	6.7	25
150	Pathophysiology of autoimmune polyneuropathies. Presse Medicale, 2013, 42, e181-e192.	1.9	25
151	Autoimmune encephalitis with GABA _B antibodies, thymoma, and GABA _B receptor thymic expression. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e39.	6.0	25
152	Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials. Neurotherapeutics, 2016, 13, 20-33.	4.4	25
153	Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications. Acta Myologica, 2020, 39, 289-301.	1.5	25
154	Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Review of Clinical Immunology, 2022, 18, 691-701.	3.0	25
155	Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Expert Opinion on Medical Diagnostics, 2010, 4, 241-250.	1.6	23
156	Blockade of blocking antibodies in Guillain-Barrï¿½ syndromes: ?Unblocking? the mystery of action of intravenous immunoglobulin. Annals of Neurology, 2002, 51, 667-669.	5.3	22
157	Immunotherapy-responsive limbic encephalitis with antibodies to glutamic acid decarboxylase. Journal of the Neurological Sciences, 2014, 343, 192-194.	0.6	22
158	Are autoantibodies pathogenic in necrotizing myopathy?. Nature Reviews Rheumatology, 2018, 14, 251-252.	8.0	22
159	Potential biomarkers for monitoring therapeutic response in patients with CIDP. Journal of the Peripheral Nervous System, 2011, 16, 63-67.	3.1	21
160	Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases. Neurotherapeutics, 2022, 19, 691-710.	4.4	21
161	Basic Principles of Immunotherapy for Neurologic Diseases. Seminars in Neurology, 2003, 23, 121-132.	1.4	20
162	Obinutuzumab, a potent antiâ€“B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e460.	6.0	20

#	Article	IF	Citations
163	Necrotising autoimmune myopathy (NAM): antibodies seem to be specific markers in aiding diagnosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1037-1037.	1.9	18
164	Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM. BMC Neurology, 2016, 16, 48.	1.8	18
165	Anti-Neuronal Antibodies Within the IVIg Preparations: Importance in Clinical Practice. Neurotherapeutics, 2020, 17, 235-242.	4.4	18
166	Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future. Annals of the New York Academy of Sciences, 2012, 1274, 1-8.	3.8	17
167	Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity. Neurotherapeutics, 2016, 13, 163-178.	4.4	17
168	Trial of canakinumab, an IL-1Î² receptor antagonist, in patients with inclusion body myositis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e581.	6.0	17
169	Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits. Expert Review of Clinical Immunology, 2022, 18, 413-423.	3.0	17
170	Progression of Oral-Motor and Swallowing Symptoms in the Post-Polio Syndrome. Annals of the New York Academy of Sciences, 1995, 753, 87-95.	3.8	16
171	Intravenous Immunoglobulin in Patients With Anti-GAD Antibody-Associated Neurological Diseases and Patients With Inflammatory Myopathies: Effects on Clinicopathological Features and Immunoregulatory Genes. Clinical Reviews in Allergy and Immunology, 2005, 29, 255-270.	6.5	16
172	Enteroviruses and Human Neuromuscular Diseases. , 0, , 387-398.		16
173	Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies. Neurotherapeutics, 2022, 19, 741-752.	4.4	16
174	The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies. Neurotherapeutics, 2022, 19, 864-873.	4.4	16
175	Gene therapy for Duchenne muscular dystrophy: balancing good science, marginal efficacy, high emotions and excessive cost. Therapeutic Advances in Neurological Disorders, 2017, 10, 293-296.	3.5	15
176	Review: Therapeutic advances and future prospects in immune-mediated inflammatory myopathies. Therapeutic Advances in Neurological Disorders, 2008, 1, 157-166.	3.5	13
177	Progressive encephalomyelitis with rigidity and myoclonus (PERM): brucellosis as a possible triggering factor and long-term follow-up therapy with rituximab. Therapeutic Advances in Neurological Disorders, 2016, 9, 69-73.	3.5	13
178	Reply: Meningitis and Skin Reaction after Intravenous Immune Globulin Therapy. Annals of Internal Medicine, 1997, 127, 1130.	3.9	13
179	Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibodyâ€“Positive Stiff-Person Syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	13
180	Rituximab in anti-MAG neuropathy: More evidence for efficacy and more predictive factors. Journal of the Neurological Sciences, 2017, 377, 224-226.	0.6	12

#	Article	IF	Citations
181	Anti-SARS-CoV-2 antibody detection in healthcare workers of two tertiary hospitals in Athens, Greece. Clinical Immunology, 2020, 221, 108619.	3.2	12
182	Treatment for inclusion body myositis. The Cochrane Library, 0, , .	2.8	11
183	IVIG efficacy in CIDP patients is not associated with terminal complement inhibition. Journal of Neuroimmunology, 2019, 330, 23-27.	2.3	11
184	Neuroimmunotherapy: A Practical Approach to the Treatment of Immune-Mediated Neurologic Diseases. Seminars in Neurology, 1994, 14, 97-105.	1.4	10
185	Role of the Muscle in Acute Poliomyelitis Infection. Annals of the New York Academy of Sciences, 1995, 753, 58-67.	3.8	10
186	Inflammatory myopathies. , 2010, , 427-452.		9
187	Reliability of the Adult Myopathy Assessment Tool in Individuals With Myositis. Arthritis Care and Research, 2015, 67, 563-570.	3.4	9
188	Antibodies to inositol 1,4,5-triphosphate receptor 1 in patients with cerebellar disease. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e306.	6.0	9
189	Autoimmune Neurogenic Dysphagia. Dysphagia, 2022, 37, 473-487.	1.8	9
190	Inclusion-body myositis in the elderly: an update. Aging Health, 2010, 6, 687-694.	0.3	8
191	Viruses in IBM. Neurology, 2016, 86, 204-205.	1.1	8
192	Limited Benefits Halt Enrollment in Hematopoietic Stem Cell Transplantation Trial for Stiff-Person Syndrome. Neurology, 2021, 96, 239-240.	1.1	8
193	Aseptic Meningitis and Intravenous Immunoglobulin Therapy. Annals of Internal Medicine, 1995, 122, 316.	3.9	8
194	Identification of macrophages in the muscle biopsy preparations: A comparative study using specific monoclonal antimacrophage antibodies and acid phosphatase reaction. Muscle and Nerve, 1995, 18, 242-244.	2.2	7
195	IVIg in the chronic management of myasthenia gravis: Is it enough for your money?. Journal of the Neurological Sciences, 2014, 338, 1-2.	0.6	7
196	Close to the node but far enough. Neurology, 2016, 86, 796-797.	1.1	7
197	Neuro-Immunotherapies: A 30-year Retrospective of an Overwhelming Success and a Brighter Future. Neurotherapeutics, 2016, 13, 1-3.	4.4	7
198	Treating myasthenia on consensus guide: Helpful and challenging but still unfinished business. Neurology, 2016, 87, 350-351.	1.1	6

#	Article	IF	Citations
199	Case 22-2019: A 65-Year-Old Woman with Myopathy. New England Journal of Medicine, 2019, 381, 1693-1694.	27.0	6
200	Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data. Neurological Sciences, 2022, 43, 2641-2649.	1.9	6
201	Immunization of mice with a peptide derived from the HTLV-1 TAX1BP1 protein induces cross-reactive antibodies against aquaporin 4. Autoimmunity, 2015, 48, 453-9.	2.6	6
202	How To Design a Therapeutic Study in Patients with the Post-Polio Syndrome.. Annals of the New York Academy of Sciences, 1995, 753, 314-320.	3.8	5
203	Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. Lancet Neurology, The, 2018, 17, 20-21.	10.2	5
204	Autoimmune peripheral neuropathies. , 2008, , 977-994.		4
205	Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	4
206	N2 year in review. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e925.	6.0	3
207	Unconvincing Evidence of SARS-CoV-2â€“Associated Myositis in Autopsied Muscles. JAMA Neurology, 2022, 79, 92.	9.0	3
208	Natalizumab therapy in patients with pediatric-onset multiple sclerosis in Greece: clinical and immunological insights of time-long administration and future directionsâ€”a single-center retrospective observational study. Naunyn-Schmiedeberg's Archives of Pharmacology, 2022, 395, 933-943.	3.0	3
209	Use of Intravenous Immunoglobulin in Neurology. , 2018, , 101-109.		2
210	Treatment of Stiff-Person Syndrome. Current Clinical Neurology, 2019, , 333-335.	0.2	2
211	Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis. Expert Review of Neurotherapeutics, 2022, 22, 313-318.	2.8	2
212	Autoimmune Peripheral Neuropathies. , 2019, , 903-915.e1.		1
213	N2 year in review. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e644.	6.0	1
214	LGI1 encephalitis with squamous lung-cell carcinoma: Resolution after tumor resection. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	1
215	Therapeutic Antibodies in Neurological Diseases: Witnessing the Continuation of the Impressive Success in Neuro-Immunotherapies. Neurotherapeutics, 2022, 19, 687-690.	4.4	1
216	PolioRedux. The Sciences, 1995, 35, 30-35.	0.1	0

#	Article	IF	Citations
217	Concluding Remarks and Future Strategies. Annals of the New York Academy of Sciences, 1995, 753, 366-369.	3.8	0
218	Autoimmune peripheral neuropathies. , 2013, , 801-811.		0
219	Progressive multifocal fibrosing neuropathy: description of a novel disease. Acta Neuropathologica Communications, 2022, 10, 34.	5.2	0